R Janknegt¹*, R Fijn², HC Alblij³ and AA Van Bodegraven⁴

¹Hospital Pharmacist/Clinical Pharmacologist, Sittard-Geleen, The Netherlands
²Hospital Pharmacist, Clinical Pharmacologist, Alrijne Healthcare Group, Leiden, The Netherlands
³Internist, Nephrologist, Alrijne Healthcare Group, Leiderdorp, The Netherlands
⁴Gastroenterologist, Zuyderland Medical Center, Heerlen-Sittard-Geleen, The Netherlands

*Corresponding Author: R Janknegt, Hospital Pharmacist/Clinical Pharmacologist, Sittard-Geleen, The Netherlands.

Received: May 25, 2021; Published: July 26, 2021

Abstract

Objectives: This analysis was performed to compare intravenous iron formulations for the treatment of iron deficiency anaemia when oral iron preparations are ineffective, contraindicated or not tolerated in any other way.

Methods: In this study intravenous iron formulations are compared by means of the SOJA method.

The following selection criteria were applied: licenced indications, contraindications, warnings and precautions, number of formulations, drug interactions, clinical efficacy, adverse effects, safety, tolerability, ease of admininstration and documentation.

Results: Overall SOJA scores differed slightly, with Ferric derisomaltose showing the highest score, followed by Ferric carboxymaltose. The scores for the other formulations were lower, especially because of the lower ease of administration.

Acquisition cost was not taken into account, because this varies with time. In practice acquisition cost is of course an important selection criterion. Exclusion of this criterion also makes this comparison more internationally applicable..

Conclusion: The present matrix may be of use for hospital formulary committees in determining preferences for specific iron formulations from a clinical practice, prior to the procurement phase.

Keywords: Intravenous Iron Formulations; Drug Selection; Ferric Carboxymaltose; Ferric Dextran Complex; Ferric Derisomaltose; Iron Sucrose

References

1. Janknegt R and Steenhoek A. “The System of Objectified Judgement Analysis. A tool in rational drug selection for formulary purposes”. Drugs 53 (1997): 550-562.
2. Beguin Y., et al. “Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial”. American Journal of Hematology 88 (2013): 990-996.
3. Okonko DO., et al. “Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial”. Journal of the American College of Cardiology 51 (2008): 103-112.
4. Bhandal N and Russell R. “Intravenous versus oral iron therapy for postpartum anemia”. BJOG 113 (2006): 1248-1252.
5. Bayoumeu F., et al. “Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route”. American Journal of Obstetrics and Gynecology 186 (2002): 518-22.
6. Rohling RG., et al. “Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin”. Journal of Hematotherapy and Stem Cell Research 9 (2000): 497-500.
7. Karkouti K., et al. “Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia”. Canadian Journal of Anaesthesia 53 (2006): 11-19.
8. Ren X., et al. “Effect of Intravenous Iron Supplementation on Acute Mountain Sickness: A Preliminary Randomized Controlled Study”. Medical Science Monitor 21 (2015): 2050-2057.
9. Beck-da-Silva L., et al. “IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia”. International Journal of Cardiology 168 (2013): 3439-3442.
10. Li H and Wang SX. “Intravenous iron sucrose in peritoneal dialysis patients with renal anemia”. Peritoneal Dialysis International 28 (2008): 149-154.
11. Dangsuwan P and Manchana T. “Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy”. Gynecologic Oncology 116 (2010): 522-525.
12. Aggarwal HK., et al. “Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin”. Journal of the Association of Physicians of India 51 (2003): 170-174.
13. Earley CJ., et al. “A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome”. Sleep Medicine 10 (2009): 206-211.
14. Erichsen K., et al. “Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease”. Scandinavian Journal of Gastroenterology 40 (2005): 1058-1065.
15. Schröder O., et al. “Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study”. American Journal of Gastroenterology 100 (2005): 2503-2509.
16. Breymann C., et al. “Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy”. American Journal of Obstetrics and Gynecology 184 (2001): 662-667.
17. Breymann C., et al. “Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex”. Journal of Perinatal Medicine 35 (2007): 115-118.
18. Dahdah K., et al. “Intravenous iron dextran treatment in predialysis patients with chronic renal failure”. American Journal of Kidney Diseases 36 (2000): 775-782.
19. Auerbach M., et al. “A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients”. American Journal of Kidney Diseases 31 (1998): 81-86.
20. Y1 Sloand JA., et al. “A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome”. American Journal of Kidney Diseases 43 (2000): 663-670.
21. Allen RP., et al. “Clinical efficacy and safety of IV ferric carboxymaltose treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial”. Sleep Medicine 12 (2011): 906-913.
22. Olijhoek G., et al. “Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial”. Transfusion 41 (2001): 957-963.
23. Hussain I., et al. “Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia”. Anemia 2013 (2013): 169107.
24. Onken JE., et al. “Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial”. Nephrology Dialysis Transplantation 29 (2014): 833-842.
25. Evstatiev R., et al. “FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease”. Gastroenterology 141 (2011): 846-853.
26. Naqash A., et al. “Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials”. BMC Womens Health1 (2018): 6.
27. Bhandari S., et al. “A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients”. Nephrology Dialysis Transplantation 30 (2015): 1577-1589.
28. Derman R., et al. “A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia”. American Journal of Hematology 92 (2017): 286-291
29. Derman R., et al. “Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia”. American Journal of Hematology6 (2018): E148-E150.
30. Bhandari S., et al. “Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial”. Nephrology Dialysis Transplantation 36 (2021): 111-120.
31. Auerbach M., et al. “A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia the FERWON-IDA trial”. American Journal of Hematology 94 (2019): 1007-1014.
32. Bisbe E., et al. “A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery”. British Journal of Anaesthesia 107 (2011): 477-478.
33. Sinha S., et al. “Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease”. Journal of Renal Care 35 (2009): 67-73.
34. Waziri B., et al. “Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria”. Clinical Kidney 9 (2016): 817-822.
35. Onken JE., et al. “A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia”. Transfusion 54 (2014): 306-315.
36. Barish CF., et al. “Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials”. Anemia 2012 (2012): 172104.
37. Anker SD., et al. “Ferric carboxymaltose in patients with heart failure and iron deficiency”. The New England Journal of Medicine 361 (2009): 2436-2448.
38. Ponikowski P., et al. “Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency”. European Heart Journal 36 (2015): 657-668.
39. Kulnigg S., et al. “A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial”. American Journal of Gastroenterology 103 (2008): 1182-1192.
40. Bager P and Dahlerup JF. “Randomized clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage--a placebo-controlled study”. Alimentary Pharmacology and Therapeutics 39 (2014): 176-187.
41. Bisbe E., et al. “Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty”. British Journal of Anaesthesia 113 (2014): 402-409.
42. Van Wyck DB., et al. “Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial”. Obstetrics and Gynecology 110 (2007): 267-278.
43. Seid MH., et al. “Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial”. American Journal of Obstetrics and Gynecology 199 (2008): 435.e1-7.
44. Damineni SC and Thunga S. “IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia”. Journal of Clinical and Diagnostic Research 10 (2016): QC08-QC10.
45. Van Wyck DB., et al. “Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial”. Transfusion 49 (2009): 2719-2728.
46. Breymann C., et al. “Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP)”. Journal of Perinatal Medicine 45 (2017): 443-453.
47. Charytan C., et al. “Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study”. Nephrology Dialysis Transplantation 28 (2013): 953-964.
48. Qunibi WY., et al. “A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients”. Nephrology Dialysis Transplantation 26 (2011): 1599-1607.
49. Macdougall IC., et al. “FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia”. Nephrology Dialysis Transplantation 29 (2014): 2075-2084.
50. Khalafallah AA., et al. “Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomized controlled trial”. Lancet Haematology 3 (2016): e415-425.
51. Moore RA., et al. “Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data”. BMC Blood Disorder 11 (2011): 4.
52. Johansson PI., et al. “Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)”. Vox Sang 109 (2015): 257-266.
53. Reinisch W., et al. “A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)”. American Journal of Gastroenterology 108 (2013): 1877-1888.
54. Birgegård G., et al. “A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial”. Pharmacotherapy 36 (2016): 402-414.
55. Kalra PA., et al. “A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia”. Nephrology Dialysis Transplantation 31 (2016): 646-55.
56. Yoo S., et al. “Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: A randomized controlled trial”. European Journal of Anaesthesiology (2020).
57. Gybel-Brask M., et al. “Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial”. Transfusion 58 (2018): 974-981.
58. Holm C., et al. “Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage”. Journal of Maternal-Fetal and Neonatal Medicine 32 (2019): 2797-2804.
59. Auerbach M., et al. “Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial”. Journal of Clinical Oncology 22 (2004): 1301-1307.
60. Auerbach M., et al. “Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia”. American Journal of Hematology 85 (2010): 655-663.
61. Bencaiova G., et al. “Iron prophylaxis in pregnancy: intravenous route versus oral route”. European Journal of Obstetrics and Gynecology and Reproductive Biology 144 (2009): 135-139.
62. Froessler B., et al. “Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial”. Journal of Maternal-Fetal and Neonatal Medicine 26 (2013): 654-659.
63. Kochhar PK., et al. “Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial”. Journal of Obstetrics and Gynaecology Research 39 (2013): 504-510.
64. Giannoulis C., et al. “Intravenous administration of iron sucrose for treating anemia in postpartum women”. Hippokratia 13 (2009): 38-40.
65. Gupta A., et al. “A randomized controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy”. Indian Journal of Hematology and Blood Transfusion 30 (2014): 120-125.
66. Bhavi SB and Jaju PB. “Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial”. BMC Pregnancy Childbirth 17 (2017): 137.
67. Westad S., et al. “A 12-week randomized study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia”. Acta Obstetricia et Gynecologica Scandinavica 87 (2008): 916-923.
68. Al-Momen AK., et al. “Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy”. European Journal of Obstetrics and Gynecology and Reproductive Biology 69 (1996): 121-124.
69. Dhanani JV., et al. “Comparison of efficacy and safety of two parenteral iron preparations in pregnant women”. Journal of Pharmacology and Pharmacotherapeutics 3 (2012): 314-319.
70. Kim YH., et al. “Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study”. Acta Haematology 121 (2009): 37-41.
71. Krayenbuehl PA., et al. “Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration”. Blood 118 (2011): 3222-3227.
72. Athibovonsuk P., et al. “Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy”. Gynecologic Oncology 131 (2013): 679-682.
73. Lindgren S., et al. “Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study”. Scandinavian Journal of Gastroenterology 44 (2009): 838-845.
74. Li H and Wang SX. “Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia”. Blood Purification 26 (2008): 151-156.
75. Van Wyck DB., et al. “A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD”. Kidney International 68 (2005): 2846-2856.
76. Charytan C., et al. “Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis”. Nephron Clinical Practice 100 (2005): c55-62.
77. McMahon LP., et al. “Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial”. Nephrology Dialysis Transplantation 25 (2010): 920-926.
78. Serrano-Trenas JA., et al. “Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial”. Transfusion 51 (2011): 97-104.
79. Hetzel D., et al. “A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy”. American Journal of Hematology 89 (2014): 646-650.
80. Hedenus M., et al. “Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study”. Leukemia 21 (2007): 627-632.
81. Garrido-Martín P., et al. “The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial”. Interactive CardioVascular and Thoracic Surgery 15 (2012): 1013-1038.
82. Madi-Jebara SN., et al. “Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery”. Journal of Cardiothoracic and Vascular Anesthesia 18 (2004): 59-63.
83. Birgegård G., et al. “High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron”. Vox Sang 99 (2010): 354-361.
84. Covic A and Mircescu G. “The safety and efficacy of intravenous ferric carboxymaltose in anemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study”. Nephrology Dialysis Transplantation 25 (2010): 2722-2730.
85. Froessler B., et al. “Intravenous ferric carboxymaltose for anaemia in pregnancy”. BMC Pregnancy Childbirth 14 (2014): 115.
86. Tagboto S., et al. “The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients”. Journal of Renal Care 35 (2009): 18-23.
87. Muñoz M., et al. “Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients”. Transfusion 54 (2014): 289-299.
88. Wikström B., et al. “Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease”. Journal of Nephrology 24 (2011): 589-596.
89. Reinisch W., et al. “A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable haemoglobin levels in inflammatory bowel disease”. Scandinavian Journal of Gastroenterology (2015): 1-8.
90. Goh HJ., et al. “Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis”. Drug Design, Development and Therapy 14 (2020): 5679-5687.
91. Auerbach M., et al. “Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia”. American Journal of Hematology 86 (2011): 860-862.
92. Cooke M., et al. “Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (Cosmofer) in patients with chronic kidney disease”. American Journal of Nephrology 35 (2012): 69-74.
93. Khalil A., et al. “Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice”. European Journal of Gastroenterology and Hepatology 23 (2011): 1029-1035.
94. Haddad A., et al. “Use of iron sucrose in dialysis patients sensitive to iron dextran”. Saudi Journal of Kidney Disease and Transplantation 20 (2009): 208-211.
95. Crary SE., et al. “Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy”. Pediatric Blood Cancer 56 (2011): 615-619.
96. Kulnigg S., et al. “Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment”. American Journal of Gastroenterology 104 (2009): 1460-1467.
97. Mircescu G., et al. “Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients”. Nephrology Dialysis Transplantation 21 (2006): 120-124.
98. Akarsu S., et al. “Treatment of iron deficiency anemia with intravenous iron preparations”. Acta Haematology 116 (2006): 51-57.
99. Crary SE., et al. “Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy”. Pediatric Blood Cancer 56 (2011): 615-619.
100. Pollock RF., et al. “A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment”. Expert Review of Hematology 12 (2019): 129-136.
101. Wysowski DK., et al. “Use of parenteral iron products and serious anaphylactic-type reactions”. American Journal of Hematology 85 (2010): 650-654.
102. European Medicines Agency, Assessment report for: Iron containing intravenous (IV) medicinal products, 13th September EMA/549569/2013 (2013).
103. Chertow GM., et al. “On the relative safety of parenteral iron formulations”. Nephrology Dialysis Transplantation 19 (2004): 1571-5.
104. Chertow GM., et al. “Update on adverse drug events associated with parenteral iron”. Nephrology Dialysis Transplantation 21 (2006): 378-382.
105. Auerbach M and Macdougall IC. “Safety of intravenous iron formulations: facts and folklore”. Blood Transfusion 12 (2014): 296-300.
106. Avni T., et al. “The safety of intravenous iron preparations: systematic review and meta-analysis”. Mayo Clinic Proceedings 90 (2015): 12-23.
107. Pollock RF and Biggar P. “Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia”. Expert Review of Hematology2 (2020): 187-195.
108. Brookhart MA., et al. “Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients”. Journal of the American Society of Nephrology 24 (2013): 1151-1158.
109. Wolf M., et al. “Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials”. JAMA 4 323.5 (2020): 432-443.
110. Schaefer B., et al. “Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis”. British Journal of Clinical Pharmacology (2020).
111. Mulder MB., et al. “Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer®) versus ferric carboxy-maltose (Ferinject®). A single center, cohort study”. British Journal of Clinical Pharmacology 85 (2019): 385-392.
112. Adkinson NF., et al. “Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial”. American Journal of Hematology (2018).
113. Sivakumar C., et al. “Safety of Intravenous Iron - Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients”. Peritoneal Dialysis International 39 (2019): 192-195.
114. Anirban G., et al. “The comparative safety of various intravenous iron preparations in chronic kidney disease patients”. Renal Failure 30 (2008): 629-638.
115. Louzada ML., et al. “Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study”. BMC Hematology 16 (2016): 7.
116. Sav T., et al. “Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?” Renal Failure 29 (2007): 423-426.
117. Solak Y., et al. “Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients”. Renal Failure 33 (2011): 307-311.
118. Bailie GR., et al. “Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia”. Hemodial International 14 (2010): 47-54.
119. Muñoz M and Martín-Montañez E. “Ferric carboxymaltose for the treatment of iron-deficiency anemia”. Expert Opinion on Pharmacotherapy 13 (2012): 907-921.
120. Keating GM. “Ferric carboxymaltose: a review of its use in iron deficiency”. Drugs 75 (2015): 101-127.
121. Wolf M., et al. “Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials”. American Journal of Hematology (2020): 1-3.
122. Dossabhoy NR., et al. “Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia”. Renal Failure 36 (2014): 1033-1107.
123. Aronoff GR., et al. “Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens”. Kidney International 66 (2004): 1193-1198.

Citation

Citation: R Janknegt., et al. “Intravenous Iron Formulations: Drug Selection by Means of the SOJA Method".Acta Scientific Pharmacology 2.8 (2021): 26-47.

Copyright

Copyright: © 2020 R Janknegt., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.